Novartis | NOVN - Gross Profit On Sales


Novartis reported $10.07B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alcon AG USD 1.69B 175M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Autolus Therapeutics Ltd USD 1.65M 2.69M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Fresenius EUR 1.51B 214M Dec/2025
Fresenius Medical Care EUR 1.18B 210M Mar/2026
Genmab DKK 977M 13M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
J&J USD 18.55B 1.31B Jun/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.07B 758M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Orion EUR 339.9M 85.9M Jun/2026
Pfizer USD 11.04B 1.24B Mar/2026
Philips EUR 1.77B 522M Mar/2026
Recordati EUR 472.65M 40.24M Dec/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025